List view / Grid view
The US Food and Drug Administration has approved first-line treatment…
19 November 2018 | By European Pharmaceutical Review
The US Food and Drug Administration has approved first-line treatment for newly diagnosed peripheral T-cell lymphoma using a new review program...
“Patients will now have an approved therapy that has been…
3 August 2018 | By European Pharmaceutical Review
“Patients will now have an approved therapy that has been shown to decrease the need for blood pressure medication and reduce tumour size in some patients.”
The FDA has approved Doptelet tablets to treat low blood…
25 May 2018 | By European Pharmaceutical Review
The FDA has approved Doptelet tablets to treat low blood platelet count in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure...
The U.S. Food and Drug Administration has approved Tafinlar and…
10 May 2018 | By European Pharmaceutical Review
The U.S. Food and Drug Administration has approved Tafinlar and Mekinist administered together, for the treatment of anaplastic thyroid cancer that cannot be removed by surgery...
The FDA has granted accelerated approval to Blincyto to treat adults and…
5 April 2018 | By European Pharmaceutical Review
The FDA has granted accelerated approval to Blincyto to treat adults and children with B-cell precursor acute lymphoblastic leukaemia (ALL)...
The FDA has approved Adcetris to treat adult patients with…
23 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has approved Adcetris to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy...
The FDA has approved Imfinzi for the treatment of patients…
21 February 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has approved Imfinzi for the treatment of patients with stage III non-small cell lung cancer whose tumours are not able to be surgically removed and whose cancer has not progressed after treatment...
The FDA has approved Lutathera for the treatment of a…
29 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has approved Lutathera for the treatment of a type of cancer that affects the pancreas the gastrointestinal tract...
The FDA has expanded the approved use of Lynparza to…
15 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has expanded the approved use of Lynparza to include the treatment of patients with metastatic breast cancer who have a BRCA gene mutation...
Hemlibra has been approved to prevent the frequency of bleeding…
20 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Hemlibra has been approved to prevent the frequency of bleeding episodes in patients who have developed FVIII inhibitors...
The FDA has expanded the approval of Zelboraf to include…
7 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has expanded the approval of Zelboraf to include the treatment of certain adult patients with Erdheim-Chester Disease, a rare cancer of the blood...
The FDA has granted accelerated approval to Calquence for the…
1 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has granted accelerated approval to Calquence for the treatment of adults with mantle cell lymphoma...
The FDA has approved Verzenio to treat advanced or metastatic…
29 September 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has approved Verzenio to treat advanced or metastatic breast cancer that has progressed after taking therapy...
The FDA has approved Mylotarg for the treatment of adults…
4 September 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has approved Mylotarg for the treatment of adults with newly diagnosed acute myeloid leukaemia whose tumours express the CD33 antigen...
The FDA has approved Besponsa for the treatment of adults…
18 August 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has approved Besponsa for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia...
Follow: